An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
Acadia Pharmaceuticals specializes in CNS therapies; a key insider recently trimmed their stake amid ongoing product pipeline developments.
Read the full articleYou might also wanna read
Business Watch: Hardware Store Closures and Industry Deals in Chemicals & Pharma
Here’s what we’re watching in the chemical and pharmaceutical industries this week
cen.acs.org·15d agoBusiness Watch: Hardware Store Closures and Industry Deals in Chemicals & Pharma
Here’s what we’re watching in the chemical and pharmaceutical industries this week
cen.acs.org·15d agoAmgen continues to defend Tavneos as global regulatory pressure mounts
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s
Insider Sell Alert: Todd Duchene Sells 10,000 Shares of Core Scientific Inc (CORZ)
Related Stocks: CORZ
AstraZeneca autosomal dominant polycystic kidney disease drug gets orphan status
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
Cadrenal Therapeutics announces clinical data from CAD-1005 study
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
Inhibikase Therapeutics' treatment of PAH granted FDA orphan designation
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
Comments
Sign in to join the conversation.
No comments yet. Be the first.